Kineta, Inc. (KANT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kineta, Inc. (KANT) has a cash flow conversion efficiency ratio of 0.153x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.22 Million) by net assets ($-7.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kineta, Inc. - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Kineta, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kineta, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kineta, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agereh Technologies Inc
V:AUTO
|
-0.001x |
|
Vision Marine Technologies Inc
NASDAQ:VMAR
|
0.608x |
|
Sultan Resources Ltd
AU:SLZ
|
-0.038x |
|
QMC Quantum Minerals Corp
V:QMC
|
0.001x |
|
Emergent Metals Corp
V:EMR
|
-0.050x |
|
Kuniko Ltd
AU:KNI
|
-0.111x |
|
1844 Resources Inc
V:EFF
|
0.704x |
|
Abits Group Inc.
NASDAQ:ABTS
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Kineta, Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Kineta, Inc. from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $3.06 Million | $-16.21 Million | -5.299x | -27.26% |
| 2022-12-31 | $4.57 Million | $-19.03 Million | -4.164x | -378.69% |
| 2021-12-31 | $-11.95 Million | $-17.85 Million | 1.494x | +1502.09% |
| 2020-12-31 | $-21.55 Million | $2.30 Million | -0.107x | -- |
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more